ALK and non-small cell lung carcinoma: One of the most common sites of progressive disease (PD) in patients with ALK-rearranged NSCLC is central nervous system (CNS), presumably due to the poor blood-brain barrier penetration of crizotinib and the development of mutations related to resistance to crizotinib [5, 8, 9].